Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention

T. J. FitzGerald, Tao Wang, Hira Lai Goel, Jiayi Huang, Gary Stein, Jane Lian, Roger J. Davis, Steven Doxsey, K. C. Balaji, Jesse Aronowitz, Lucia R. Languino

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.

Original languageEnglish
Pages (from-to)967-974
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume8
Issue number6
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Keywords

  • Casodex®
  • IGF-IR
  • Integrin
  • Prostate cancer
  • Radiation therapy

Fingerprint Dive into the research topics of 'Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention'. Together they form a unique fingerprint.

  • Cite this

    FitzGerald, T. J., Wang, T., Goel, H. L., Huang, J., Stein, G., Lian, J., Davis, R. J., Doxsey, S., Balaji, K. C., Aronowitz, J., & Languino, L. R. (2008). Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Review of Anticancer Therapy, 8(6), 967-974. https://doi.org/10.1586/14737140.8.6.967